Date: 2016-05-24
Type of information: Production agreement
Compound: CB 813d (recombinant factor VIIa)
Company: Catalyst Biosciences (USA - CA) CMC Biologics (Denmark)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: production manufacturing
Action mechanism: protein/blood coagulation factor. CB 813d,is a next-generation Factor VIIa that successfully completed a Phase 1 clinical trial in 2015 in severe hemophilia A and B with and without inhibitors. CB 813d is initially being developed for the on-demand and prophylactic treatment of severe hemophilia A and B patients with inhibitors. CB 813d was designed to combine higher clot-generating activity at the site of bleeding and improved duration of action.
Disease: hemophilia A, hemophilia B
Details: * On May 24, 2016, Catalyst Biosciences and CMC ICOS Biologics announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.
Financial terms:
Latest news:
